FDA approves Genpharm’s application for Zaleplon

6/9/2008

PITTSBURGH The Food and Drug Administration has granted final approval for Mylan subsidiary Genpharm’s application for 5mg and 10mg Zaleplon Capsules, Mylan announced Monday.

Zaleplon Capsules are a generic version of King Pharmaceuticals’ Sonata Capsules, which treat insomnia. Mylan announced that it would begin marketing the capsules immediately under the Mylan Pharmaceuticals brand.

Sonata had sales of $88 million during the 12 months ending March 31, according to IMS Health data.

X
This ad will auto-close in 10 seconds